NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg
Claude Maraoui
President & Chief Executive Officer
Claude has more than 30 years of experience in commercializing some of the most successful dermatology products in the world. He served as Vice President of Dermatology Sales at Medicis Pharmaceutical Corporation and has held various leadership positions in marketing and sales for therapeutic and aesthetic dermatology. He has executed more than 50 product launches during his career. In 2012, Valeant Pharmaceuticals International Inc. acquired Medicis for approximately $2.6B. Claude received his B.S. in Business and Marketing from Rutgers University.
Joseph Benesch
Chief Financial Officer
Joe has over 25 years of financial and business experience, predominantly in the pharmaceutical industry. He previously served as Vice President, Corporate Controller and Principal Accounting Officer of Telligent Pharma Inc., a specialty generic pharmaceutical company, and Corporate Controller of Torrent Pharmaceuticals a U.S. subsidiary the Torrent Group, a multinational pharmaceutical company. Joe has held senior financial management positions of increasing responsibility from corporate controller to Vice President of Finance at Savient Pharmaceuticals, Adare Pharmaceuticals and Edenbridge Pharmaceuticals. He began his career in the public accounting sector at Baker Tilly Virchow Krause, LLP, and Ernst and Young working with a diverse client base. Joe is a graduate of Wilkes University where he earned a BA in accounting.
Robert Nevin
Chief Commercial Officer
Robert has more than 24 years of experience in pharmaceutical, lab and medical management, and oversees all sales, trade and managed care functions at Journey. He came to Journey from The Dermatology Alliance, where he served as Managing Partner for one of the nation’s largest independent physician associations in the specialty of dermatology. Robert received his B.S. in Business Administration and Finance from Seton Hall University.
Ramsey Alloush
General Counsel
Ramsey is responsible for all global legal matters and serves as a key advisor to the Chief Executive Officer and Board of Directors. He was appointed Company Secretary in 2021 and also serves as the Chief Compliance Officer. In addition to leading the Company’s IPO, he has led several large transactions and Hatch-Waxman litigations. Prior to joining Journey, he represented and advised biopharmaceutical companies on corporate transactions and securities matters. He also served as a legal advisor at the Securities & Exchange Commission focusing on enforcement matters. Earlier in his career, he worked in the Aesthetics Division at Medicis Pharmaceuticals. Ramsey received his LL.M. in Taxation and LL.M. in Securities & Financial Regulation from Georgetown University Law Center and his J.D. from the Shepard Broad Law Center. He has been recognized by Super Lawyers as a Rising Star in Healthcare for Washington D.C.
Srinivas Sidgiddi, M.D.
Vice President, Research & Development
Dr. Sidgiddi spent many years as a clinical practitioner and as a government medical officer in India, before moving into the pharmaceutical industry. Dr. Sidgiddi has more than 18 years of experience in NCE development, drug repositioning and translational medicine. His experience spans across multiple therapeutic areas of diabetology, oncology, medical nutrition, and dermatology. Prior to joining Journey, Dr. Sidgiddi was with Dr. Reddy’s Laboratories Inc. in New Jersey, leading their dermatology franchise to a successful 5 NDA approvals. Among others, Dr. Sidgiddi has also led clinical and translational research at Abbott Nutrition R&D, and Connexios Life Sciences in India. Dr. Sidgiddi received his Bachelor of Medicine, Bachelor of Surgery (M.B.B.S) from Gulbarga University, and his M.D. (Clinical Pharmacology) with the first rank from Rajiv Gandhi University of Health Sciences, Bangalore in India.
Andrew Zwible
Vice President, Operations
Andrew has more than 10 years of experience in dermatology pharmaceuticals, working for Medicis and Valeant as a forecasting and analytics expert. At Medicis, he assisted with the $455MM acquisition of Graceway Pharmaceuticals LLC and the sell-side $2.6B acquisition of Medicis. He has previous experience in investment banking and financial analysis. Andrew received his B.S. in Biomedical/Medical Engineering from Johns Hopkins University, his M.S. in Health Care Administration/Management from Arizona State University and his M.B.A. in Finance from Arizona State University.
Ernest Galvan
Vice President, Business Development
Ernest has more than 26 years of experience in the dermatology pharmaceutical industry. With more than 23 years in brand management and development, he has translated concepts into powerful marketing and brand solutions for a variety of dermatologic lines. Prior to Journey, his experience includes Bristol Myers Squibb, Medicis, Ranbaxy and Sun Dermatology. Ernest received his B.B.A. in Marketing from Stephen F. Austin State University and his M.B.A. in Marketing from La Salle University.
Jessica Yeaman
National Sales Director
Jessica has more than 17 years of experience in dermatology pharmaceuticals. She has been recognized for her consistent sales accomplishments during that time. Jessica has held leadership roles in sales training, marketing, and management. Prior to Journey, her experience includes Medicis, Valeant, PuraCap and Prugen Pharmaceuticals. Jessica received her B.A. in Communications from Palm Beach Atlantic University.